

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

761427Orig1s000

Trade Name: LEROCHOL injection

Generic or Proper Name: Lerodalcibep-liga

Sponsor: LIB Therapeutics, Inc.

Approval Date: December 12, 2025

Indication: as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)

CENTER FOR DRUG EVALUATION AND RESEARCH

761427Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Integrated Review(s)	X
Product Quality Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761427Orig1s000

APPROVAL LETTER



BLA 761427/Original 1

BLA APPROVAL

LIB Therapeutics, Inc.
Attention: Evan A. Stein, MD, PhD
Chief Executive and Scientific Officer
5375 Medpace Way
Cincinnati, OH 45227

Dear Dr. Stein:

Please refer to your biologics license application (BLA) dated and received December 12, 2024, and your amendments, under section 351(a) of the Public Health Service Act for Lerochol (lerodalcibep-liga) injection.

BLA 761427 provides for the use of Lerochol (lerodalcibep-liga) for the following indications which, for administrative purposes, we have designated as follows:

- BLA 761427/Original 1 – Lerochol is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

(b) (4)

The subject of this action letter is BLA 761427/Original 1.

(b) (4)

All future submissions to BLA 761427/Original 1 (b) (4) should specify the BLA number and the Original number to which each submission pertains.

LICENSING

We are issuing Department of Health and Human Services U.S. License No. 2352 to LIB Therapeutics, Inc., Cincinnati, Ohio, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Lerochol (lerodalcibep-liga). Lerochol is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture Lerochol drug substance at (b) (4). The final formulated drug product in single-dose prefilled syringe will be manufactured and filled at (b) (4). The prefilled syringe plunger rod insertion, labeling, and secondary packaging will be performed at (b) (4). You may label your product with the proprietary name, Lerochol, and market it in single-dose prefilled syringe: 300 mg/1.2 mL, injection.

DATING PERIOD

The dating period for Lerochol shall be 27 months from the date of manufacture when stored at $5 \pm 3^{\circ}\text{C}$ inclusive of 3 months storage at room temperature ($20^{\circ}\text{C} - 25^{\circ}\text{C}$), protected from light. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) $^{\circ}\text{C}$, (b) (4).

We have approved the stability protocol in your license application for the purpose of extending the expiration dating period of your drug substance under 21 CFR 601.12.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Lerochol to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Lerochol, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL AND LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling and carton and container labeling submitted on December 4, 2025, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761427/Original 1.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Lerochol was not referred to an FDA advisory committee because evaluation of the safety data when used in the treatment of hypercholesterolemia did not raise significant safety or efficacy issues that were unexpected for a drug of this class. In addition, there were no controversial issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We are waiving the pediatric study requirement for ages 0 to less than 6 years because necessary studies are impossible or highly impracticable. This is because management of HeFH for children who are less than 6 years of age focuses on diet and lifestyle modification.

We are deferring submission of your pediatric study for ages 6 to less than 18 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 601.28 and section 505B(a)(4)(B) of the Federal Food, Drug, and Cosmetic Act. This required study is listed below.

- 4928-1 Conduct a double-blind, placebo-controlled, parallel group design study followed by an open-label extension to assess the efficacy and safety of lerodalcibep in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) aged 6 years to less than 18 years.

Final Protocol Submission: February 2026

Study Completion: July 2028

Final Report Submission: October 2028

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Submit the protocol(s) to your IND 134579, with a cross-reference letter to this BLA. Reports of this required pediatric postmarketing study must be submitted as a BLA or as a supplement to your approved BLA with the proposed labeling changes you believe are warranted based on the data derived from this study. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

³ See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

U.S. Food and Drug Administration

Silver Spring, MD 20993

www.fda.gov

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

- 4928-2 Conduct “aged” stability studies on at least three commercial or representative lerodalcibep PFS DP batches stored under long-term conditions for at least 24 months. The “aged” stability study conditions will include storage of the PFS DP batches at worst-case short-term storage conditions of $30\pm 2^{\circ}\text{C}$ for at least three months and consist of data from at least four timepoints, inclusive of the start and end points of the short-term study. The batches will be tested for product quality according to the lerodalcibep PFS DP stability specifications found in 3.2.P.8.2 Table 3. Provide the data in the PMC report at the completion of the studies.

The timetable you submitted on October 10, 2025, states that you will conduct this study according to the following schedule:

Final Report Submission: December 2026

Submit clinical protocols to your IND 134579 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.⁴

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR

⁴ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.
U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁵ Information and Instructions for completing the form can be found at FDA.gov.⁶

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁶ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, contact Ron Picking, Regulatory Project Manager, at 240-402-3211 or ronald.pickingiii@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Lisa B. Yanoff, MD
Deputy Director
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LISA B YANOFF
12/12/2025 01:55:20 PM